We are currently making some changes to how orders are placed and because of this there will be a
short disruption period affecting order processing. Thank you for your patience while we work to
operate as smoothly as possible (November 14, 2023).
RCi002-B
FP5C-16, RCi93
iPSC line
Purchases have been temporarily disabled, as we are transitioning sales and distribution.
If you are interested in purchasing this cell line, please contact EBiSC directly. For more information about the current transition process see here.
If you are interested in purchasing this cell line, please contact EBiSC directly. For more information about the current transition process see here.
A CLIP contains information about a cell line including any
specific third party obligations relating to, for example,
licensing obligations or the donor consent which affect the
use of the cell line.
The EBiSC Access and Use Agreement must be completed along with an individual
Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org
for countersignature. The EAUA must be fully signed before proceeding with your order.
A batch specific Certificate of Analysis will be available to
download once you receive your EBiSC iPSC line.
General#
Cell Line |
|
| hPSCreg Name | RCi002-B |
| Alternative name(s) |
FP5C-16, RCi93
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
|
Provider |
|
| Depositor | Pfizer Limited - Pfizer (PFIZ) |
| Owner | Stem Cell Research Laboratory |
| Distributors |
EBiSC
European Collection of Authenticated Cell Cultures (ECACC)
|
External Databases |
|
| hPSCreg | RCi002-B |
| BioSamples | SAMEA3106075 |
| Cellosaurus | CVCL_9S44 |
| CLO | CLO_0101561 |
| Wikidata | Q54949501 |
General Information |
|
| Publications | View all related publications on hPSCreg (1) |
| * Is the cell line readily obtainable for third parties? |
Yes |
Donor Information#
General Donor Information |
|
| Sex | female |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA3105889 |
hIPSC Derivation#
General |
|
| Source cell type |
erythroblastA nucleated precursor of an erythrocyte that lacks hematopoietic lineage markers.
Synonyms
|
| Source cell type (free text) | Blood - PBMC erythroblasts |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions#
Latest released batch |
|
| Culture medium | mTeSR |
| Passage method | EDTA |
| Surface coating | Matrigel / Geltrex |
| O2 concentration | 21 |
| CO2 concentration | 5 |
| Temperature | 37 |
The following are the depositor culture conditions, they do not refer to any specific batch.
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 21 % |
| CO2 Concentration | 5 % |
| Medium |
mTeSR™ 1
|
Characterisation#
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|
||||
| SSEA-4 |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
||||
| SSEA-1 |
No |
|
Differentiation Potency
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Genotyping#
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
18 out of 20 cells normal, one cell 45,X,add(X)(q22),-11, one cell 45,XX,-22
Passage number: P15
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
|